

Special Issue

Genes Networking Analysis Applied to Immune Response in Lung Cancer

Message from the Guest Editor

Lung cancer is the most frequent cause of cancer death worldwide, representing one of the most significant challenges in oncology. In recent years, immunotherapy, specifically therapy with immune checkpoint inhibitors (ICIs), has revolutionized the therapeutic paradigm, demonstrating durable antitumor effects in different types of cancers, including lung cancer. To date, the mechanism of action of these new therapies is still under study, since only a fraction of patients benefit from ICIs, and the only known predictive biomarker, PD-L1, is insufficient to predict immunotherapy response. Thus, identifying new potential biomarkers and understanding the tumor and immune system interactions are crucial aspects for improving patients outcomes. Advanced sequencing technologies integrated with systems biology approaches are giving rise to large-scale study and can help toward the discovery of specific gene expression signatures associated with immune response in patients.

For this Special Issue, we are soliciting state-of-the-art work in genes networking analysis applied to immune response in lung cancer, in order to collect the most recent advances in this field all in one place.

Guest Editor

Dr. Fortunato Bianconi

Department of Experimental Medicine, University of Perugia, 06128 Perugia, Italy

Deadline for manuscript submissions

closed (30 June 2021)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/60354

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Department of Pathology, The University of Alabama at Birmingham,
1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))